Objective: To investigate differences in methylation between patients with nondysplastic Barretts' oesophagus who progress to invasive adenocarcinoma and those that do not.
INTRODUCTION
Oesophageal adenocarcinoma (OADC) incidence is increasing [1] and currently forms 5% of the digestive tract cancers in the UK [2] . Overall disease survival is poor [3] but correlates with stage of cancer at presentation, demonstrating significant survival advantages with detection of early stage disease [4, 5] .
Barrett's Oesophagus (BO), in which normal squamous mucosa changes to a columnar epithelium, results from prolonged exposure to stomach acids and bile salts which reflux into the oesophagus causing chronic inflammation and tissue damage [6] .
The incidence of BO is increasing, largely thought to be a consequence of obesity induced reflux disease [7, 8, 9, 10] . Over time, driven by chronic inflammation, metaplastic change is observed and is associated with an increased risk of OADC [11] . For the majority of patients, BO will never progress beyond this benign metaplastic cell change [12, 13] . However, in a small number of patients, dysplasia will develop with some progressing to OADC [14] . The incidence of OADC in the BO population is up to 150 times greater than unaffected individuals [12] .
Although the pathological changes seen in Barrett's adenocarcinoma are understood as part of a well-established metaplasia-dysplasia-carcinoma sequence, a process driven by chronic inflammation [15] , the molecular drivers are less clear The current dilemma is that for patients with non-dysplastic BO, there are no accurate methods for identifying the small number of patients at high risk of progression to cancer.
Surveillance practice of the Barrett's patient varies widely, between some who endoscope patients each year in contrast to others who will never repeat the investigation [16] . The on-going MRC funded BOSS study aims to understanding the optimum surveillance strategy, randomising between prospective monitoring BO patients with frequent endoscopic assessment or a "watch and wait" policy [17] .
Clearly, there is need for a method of risk stratification in these patients in order to facilitate a streamlined surveillance programme by identifying high risk nondysplastic BO patients. Attempts at biomarker development for stratification of high risk Barretts oesophagus have focused on mutational change, specifically around the role of TP53 mutation in predicting "high risk" disease [18] given its role as a driver in oesophageal cancer. However Fitzgerald et al [19] have convincingly demonstrated the presence of pathogenic TP53 mutations in apparently normal squamous oesophageal mucosa thus making its role in progression to invasive adenocarcinoma unclear. However, the role of epigenetic change in the pathogenesis of Barretts oesophagus and oesophageal cancer is less well understood, but may well happen much earlier in the cancer developmental pathway and, as a direct result, provide a more appropriate target for both predicting its development and potentially arresting tumourgenesis, should a suitable epigenetic modulator be identified.
Multiple methylation markers have been identified which can discriminate between high risk and low risk BO including APC/ p16 [20] , MGMT [21] , PKP-1 [22] , TIMP3/TERT [23], RUNX3/HPP1 [24] [25] and AKAP12 [26] . Agarwal et al [27] performed an MeCIP array based approach to compare the methylomes of progressor vs. non-progressing patients. In patients that progressed to invasive adenocarcinoma, their original biopsies began either with no dysplasia, indefinite dysplasia or low grade dysplasia, making comparison difficult. However, subsequent analysis of the top 25 differential methylation patterns found three gene regions with hypermethylation amongst the progression group (Pro_MMD2, Pro_ZNF358 and Intra_F10) with a trend otherwise towards global hypomethylation, in keeping with other epithelial pre-malignant conditions [28] .
While the studies reviewed do show variation in methylation between progressive vs. non-progressive BO, the methodology has been heterogeneous and few have conducted the study with a group of the same patients tracked over time.
AIMS
To determine whether there are differences in methylation in patients between high risk non-dysplastic Barrett's Oesophagus which will progress to cancer vs low risk Barrett's
METHODS

Patients and Samples:
Two sample cohorts were identified containing patients who either progressed to OADC from non-dysplastic BO or remained with non-dysplastic BO (NDBO) identified from a prospectively maintain database of patients with BO at Sandwell & West Birmingham NHS Trust. Inclusion criteria for the study were progressing patients with non-dysplastic Barretts oesophagus who, when observed over the study period, developed OADC. Samples were only included where there was a NDBO biopsy and then histology evidence that the patient developed adenocarcinoma. Non-progressing patients were identified from a biopsy of NDBO which when followed over time never progressed beyond NDBO. To be included in this group, the patient must have been in a surveillance programme for a minimum of 15 years and have serial biopsies over that period. They were also required to have still been alive and to have had a NDBO biopsy within 2 years of this study.
Patients were excluded from the study if BO material was only available as part of tumour associated BO or if dysplasia was identified in any BO biopsies.
All tissue used was formalin fixed paraffin embedded (FFPE) samples obtained from 
Methylation Arrays
The Illumina HumanMethylation 450 array, in which the methylation status of more than 485,000 individual CpG sites are examined [29] was used to compare sample groups (progressing NDBO vs non-progressing NDBO). Once bisulphite converted, 1ng of DNA was quality controlled (Illumina FFPE QC kit) with only samples with dCt <5 being taken forward to array analysis. The resulting samples underwent repair suitable for array hybridisation using the Illumina FPPE restore kit. [30] followed by hybridisation to Illumina HumanMethylation450 arrays using manufacturers protocols and scanned on an Illumina iScan. Normalised intensity files (iDAT) were exported using GenomeStudio for downstream analysis.
Immunohistochemistry
In order to understand the effect of methylation on the expression of OR3A4 correlation of OR3A4 expression as determined by immunohistochemistry (IHC) vs.
progressor/non-progressor status was carried out. IHC was carried out on a Leica
Bond RX system using the a mouse polyclonal anti-OR3A4 antibody (Abcam ab67107) at a dilution of 1:100 with a primary incubation time of 15 minutes.
IHC was scored on epithelial and stromal components and a composite score consisting of the sum of expression within membranous, nuclear and cytoplasmic compartments on a score of 1-4 was made. Scoring was carried out by two independent observers blinded to progressor/non-progressor status.
Bioinformatic Analysis of Array Data
Bioinformatics analysis of the methylation microarrays was carried using the ChAMP 
Methylation microarray analysis
Twenty four samples in total were hybridised successfully to Illumina HumanMethylation450 microarrays. All arrays passed manufacturers QC as specified by metrics in Illumina GenomeStudio. Differential methylation analysis at the probe level (Table 1 ) revealed significant differences in methylation between progressor and non-progressors in non-dysplastic BO (Figure 1 ). In total, 44 significantly (defined as Bayes Factor, BF>5) differentially methylated targets were identified, the bulk being hypomethylated, with a trend towards global hypomethylation in progressor samples. We took advantage of the information provided by the two colour Illumina Infinium chemistry to call copy number aberrations (CAN) within the regions targeted by the methylation probes using the CNA calling function of CHAMP. This did not demonstrate any recurrent copy number alterations between progressors and nonprogressors. There were no significant differences in the numbers of CNA between the two groups, with a median of 43 CNA (range 24-92) in the progressors vs. 44 CAN (range 30-52) in the non-progressors (p=1.0, Wilcoxon rank sum).
Pathway methylation analysis was carried out using DAVID. Initially KEGG pathway analysis showed that genes associated with MAPK signalling were enriched in the dataset (p=0.012). Gene ontology analysis using the UP_KEYWORDS feature showed significant enrichment for the disease mutation (p=9.6x10-6), polymorphism (p=1.7x10-5), glycoprotein (p=3.4x10-5), and alternate splicing (p=1.1x10-4) terms.
Validation pyrosequencing
Because of the likely biological relevance of FGFR2, and the data demonstrating that OR3A4 was the top differentially methylated CpG, validation pyrosequencing was carried out on all 67 patients. Normality of distribution of methylation values was ascertained by histogram plots, in which it was found that methylation was nonnormally distributed, therefore non-parametric testing was carried out For OR3A4 cg09890332, median methylation was 67.8% in progressors vs. 96.7% in non-progressors (p=0.0001, z = 5.158, Wilcoxon rank sum test) ( Figure 2 
Expression of OR3A4 in progressors vs. non-progressors
For the stromal compartment, a median expression of 6 (IQR 4-7) was seen in 
Ability of OR3A4 methylation to act as a discriminator in BO
In order to understand the accuracy of using methylation within cg09890332 of OR3A4 as a biomarker for high risk Barretts oesophagus we further carried out a multivariate reverse stepwise logistic regression analysis of methylation at the three tagged CpG dinucleotides within the pyrosequencing assay as the independent variables and progressor vs. non-progressor status status as the dependent variable.
In this model, CpGs two and three became non-significant (p=0.3325 and p=0.4764) and were removed from the model, leaving the first CpG in cg09890332 as being significant (coef =-0.0563, SE=0.016, z=-3.40,p=0.001,95% CI -0.089--0.024). Using ROC modelling the AUC of this model was 0.82 (95% CI 0.80-0.83).
We then further used the diagt function of Stata 11.2 to model a set methylation threshold effect on sensitivity and specificity of the test, aiming for maximum negative predictive value and correcting for a incidence rate within the cohort of 0.7%.
Modelling at a threshold of below 89% being significant showed that hypomethylation at OR3A4 can predict progression to invasive carcinoma with a sensitivity of 70.8%, specificity of 86%, positive predictive value of 85% and negative predictive value of 72.5%.
CONCLUSIONS
We have identified that hypomethylation at cg09890332 corresponding to the CG nucleotide at position (CHR) of OR3A4 can discriminate patients who progress from non-dysplastic Barrett's oesophagus to those who did not. This association is maintained across independent cohorts, and seems to be related temporally as well as by case status. We observed hypomethylation within these samples up to 13 years before the development of invasive adenocarcinoma suggesting this is an early event in the development of malignant change.
The effect of hypomethylation on the OR3A4 gene seems to be functional, in that immunohistochemistry reveals a change in increased OR3A4 expression in samples with hypomethylation. The finding that the stromal expression in particular is increased is of interest given the known effect of "pathological" stroma in the pathogenesis of oesophageal cancer. Our observed region co-incides within 225bp of a CTCF and RAD21 transcription factor binding site, further suggesting that methylation there has a function effect to prevent transcription factor binding and alter gene expression. Guo et al [33] performed a genomewide screen of long noncoding RNAs in gastric adenocarcinoma, finding that OR3A4 was significantly (55.9
fold,) over-expressed in these patients. They also observed that levels of OR3A4
were correlated with metastatic potential and prognosis. Furthermore, they utilised We found both at the individual probe level and as part of a differentially methylated region that there is hypomethylation in the CpG island associated with FGFR2, however this did not validate at the single probe level when examined with bisulphite pyrosequencing. FGFR2 has been observed to undergo recurrent alteration in both oesophageal adenocarcinoma [34] and squamous cell carcinoma [35] with the latter demonstrating recurrent amplification. The disparity between our microarray results and validation by pyrosequencing may be due to probe inflation caused by small sample size, however given its biological associations with oesophageal adenocarcinoma further work is needed.
In common with pre-malignant lesions in cancer, such as colorectal adenomatous polyps [28] , we observed a trend towards genome wide hypomethylation suggesting a widespread over-expression of genes as part of the development towards malignancy. We also found no difference in chromosomal instability between progressors and non-progressors, although there was widespread instability within both sets of samples, in common with what has previously been observed [36] in Barretts oesophagus.
This methylation marker, although seemingly highly accurate for the detection of progression of Barrett's to invasive adenocarcinoma, is likely to be of more utility as a multi-modal stratifier in Barrett's oesophagus, taking account of previous findings at the mutational and copy number level, as well as epigenetic change. However, for the purpose of designing a surveillance programme with the ability to risk stratify the non-dysplastic Barretts oesophagus patient, this marker has significant potential utility. 
Development
